Effects of long-term scopolamine treatment on cognitive deficits and calcium binding proteins immunoreactivities in the mouse hippocampus
- Authors
- Ahn, Ji Hyeon; Chen, Bai Hui; Yan, Bing Chun; Park, Joon Ha; Kang, Il Jun; Lee, Tae-Kyeong; Cho, Jeong Hwi; Shin, Bich-Na; Lee, Jae-Chul; Jeon, Yong Hwan; Hong, Seongkweon; Lee, Young Joo; Choi, Soo Young; Won, Moo-Ho
- Issue Date
- Jan-2018
- Publisher
- Spandidos Publications
- Keywords
- scopolamine; memory impairments; calcium binding proteins; CA1-3 region; dentate gyrus
- Citation
- Molecular Medicine Reports, v.17, no.1, pp 293 - 299
- Pages
- 7
- Journal Title
- Molecular Medicine Reports
- Volume
- 17
- Number
- 1
- Start Page
- 293
- End Page
- 299
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6320
- DOI
- 10.3892/mmr.2017.7928
- ISSN
- 1791-2997
1791-3004
- Abstract
- GABAergic projections terminate on numerous hippocampal interneurons containing calcium binding proteins (CBPs), including calbindin D-28k (CB), calretinin (CR) and parvalbumin (PV). Memory deficits and expression levels of CB, CR, and PV were examined in the hippocampal subregions following systemic scopolamine (Scop; 1 mg/kg) treatment for 4 weeks in mice. Scop treatment induced significant memory deficits from 1 week after Scop treatment. CB, CR and PV immunoreactivities distributions were in hippocampal subregions [CA1 and CA3 regions, and the dentate gyrus (DG)]. CB immunoreactivity (CB+) was gradually decreased in all subregions until 2 weeks after Scop treatment, and CB+ was decreased to the lowest level in all subregions at 3 and 4 weeks. CR+ in the CA1 region was gradually decreased until 2 weeks and hardly observed at 3 and 4 weeks; in the CA3 region, CR+ was not altered in all subregions at any time. In the DG, CR+ was gradually decreased until 2 weeks and lowest at 3 and 4 weeks. PV+ in the CA1 region was not altered at 1 week, and gradually decreased from 2 weeks. In the CA3 region, PV+ did not change in any subregions at any time. In the DG, PV+ was not altered at 1 week, decreased at 2 weeks, and lowest at 3 and 4 weeks. In brief, Scop significantly decreased CBPs expressions in the hippocampus 3 weeks after the treatment although memory deficits had developed at 1 week. Therefore, it is suggested that Scop (1 mg/kg) must be systemically treated for 3 weeks to investigate changes in expression levels of CBPs in the hippocampus.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Emergency Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.